Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 22, 2026
YAP1 defines an emergent, plastic population of relapsed small cell lung cancer
C Allison Stewart, Kavya Ramkumar, Runsheng Wang, et al.
JTO Clinical and Research Reports
|
March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
Simon Heeke, Saumil Gandhi, Hai T Tran, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS
Bingnan Zhang, Laura Alder, Samuel Rosner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 4, 2024
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma
Kelsey L Corrigan, Ting Xu, Yuki Sasaki, et al.
Nature Cancer
|
February 1, 2021
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C Allison Stewart, Carl M Gay, Yuanxin Xi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2024
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review
Yang Xia, Kaiwen Wang, Jing Zhao, et al.
British Journal of Cancer
|
April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer
Melissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
JTO Clinical and Research Reports
|
August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
Kaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report
Bingnan Zhang, Komal B Shah, Mitchell Parma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Carminia M Della Corte, Triparna Sen, Carl M Gay, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 22, 2026
YAP1 defines an emergent, plastic population of relapsed small cell lung cancer
C Allison Stewart, Kavya Ramkumar, Runsheng Wang, et al.
JTO Clinical and Research Reports
|
March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
Simon Heeke, Saumil Gandhi, Hai T Tran, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS
Bingnan Zhang, Laura Alder, Samuel Rosner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 4, 2024
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma
Kelsey L Corrigan, Ting Xu, Yuki Sasaki, et al.
Nature Cancer
|
February 1, 2021
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C Allison Stewart, Carl M Gay, Yuanxin Xi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2024
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review
Yang Xia, Kaiwen Wang, Jing Zhao, et al.
British Journal of Cancer
|
April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer
Melissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
JTO Clinical and Research Reports
|
August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
Kaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report
Bingnan Zhang, Komal B Shah, Mitchell Parma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Carminia M Della Corte, Triparna Sen, Carl M Gay, et al.
Page
of 8